THURSDAY, Aug. 25, 2022 (HealthDay News) -- Higher CXCL9 levels are associated with increased risk for hip fracture among men, but not women, according to a study published online July 10 in the Journal of Bone and Mineral Research.
Quang Tien Phan, Ph.D., from the National University of Singapore, and colleagues conducted a case-control study nested in the prospective, population-based Singapore Chinese Health Study involving 55 men and 119 women with incident hip fractures matched for age at recruitment, gender, and duration of blood storage to controls. Immunoassays were used to measure serum chemokines, CXCL9, and CXCL10.
The researchers found that in men, but not in women, increasing CXCL9 levels were associated with an increasing risk for hip fracture. The odds ratios in the highest quartile compared with the lowest quartile were 10.35 (95 percent confidence interval, 1.90 to 56.39) and 1.46 (95 percent confidence interval, 0.59 to 3.60) in men and women, respectively. The area under the receiver operating characteristic curve was improved from 0.65 to 0.74 for predictive utility of hip fractures in men, but not women, by adding CXCL9 to a prognostic model that already incorporated age and other risk factors. The association between CXCL10 and risk for hip fracture was not statistically significant for men or women.
"Our findings open the exciting possibility that early interventions targeting CXCL9 or CXCL9-CXCR3 signaling could be beneficial in preventing hip fractures in older men," a coauthor said in a statement.